DaVita Inc. (DVA) Down 7.2% — Should I Secure What's Left?
DaVita Inc. (DVA) is buckling under pressure on Tuesday, last changing hands at $173.51 on the NYSE — a $13.49 decline from the prior close of $187.00. The selloff deepens a slide that has been building for more than two months. DVA now trades roughly 29.9% below its 52-week high of $247.49, a level it reached on August 3, 2026, the day before the company reported second-quarter results. Giving back nearly a third of its value from that peak puts the stock in a markedly weaker position than its recent fundamentals would suggest.
Volume is running at about 1.55 million shares against a 90-day average of roughly 771,000. That is double the stock's typical turnover, and the session is not yet complete.
Why DaVita Inc. Price is Moving Lower
The clearest driver of today's decline is news from Washington, not the income statement. On October 20, the Department of Health and Human Services launched its Kidney Care National Plan. The plan calls for more competition and fewer barriers to entry in dialysis, expanded home-care options, and policy changes intended to improve early treatment of kidney disease. For DaVita, the most pointed element is the plan's view of market concentration. DaVita and Fresenius (FMS) together account for roughly 74% of the dialysis market, and the plan argues that this kind of consolidation can support higher prices. A federal policy framework that directly frames the industry's structure as a problem lands squarely on the company with the largest footprint in it.
The divergence from the broader group confirms this is a company-specific repricing. Medtronic plc (MDT) gained 1.59% and HCA Healthcare, Inc. (HCA) rose 1.44% on the same day, so the broader Health Care sector is not under pressure. The market appears to be pricing in the risk of new entrants, pressure on DaVita's market position, or eventual reimbursement changes. Those risks deserve weight, but the plan's measures are proposed policy directions rather than rules already in effect. How quickly, or whether, they translate into actual competitive or pricing changes remains an open question.
The policy shock arrives despite solid recent operating results. DaVita's Q2 report on August 4 showed adjusted diluted EPS of $4.02, ahead of the $3.88 estimate. Revenue came in at $3.554 billion against expectations of about $3.50 billion and was up 5.2% year over year. Diluted EPS climbed from $2.58 a year earlier to $4.02, and management held its full-year 2026 EPS guidance at $14.10 to $15.20. Even so, the stock has drifted lower since peaking the day before that report, which suggests investors were already reluctant to pay up for the name. The next checkpoint is close. DaVita reports Q3 results after the market closes on October 29, with a 5:00 p.m. ET conference call, and management's response to the HHS plan is likely to draw as much attention as the numbers themselves.
What is the DaVita Inc. Rating - Should I Sell?
Weiss Ratings assigns DVA a B- rating. Current recommendation is Buy. The rating reflects a business whose earnings engine remains in good working order. The minus modifier acknowledges that the stock's recent behavior has not matched the strength of those fundamentals, and today's policy-driven drop reinforces that caution.
The fundamental case starts with an Excellent rating on the Growth Index. Revenue growth of 5.17% is steady rather than spectacular for a mature dialysis operator. What lifts the Growth rating is the earnings side, where quarterly diluted EPS rose from $2.58 to $4.02 year over year and trailing EPS stands at $12.22. The Good rating on the Efficiency Index draws support from an 88.48% ROE, a figure that partly reflects DaVita's lean equity base. That ROE sits alongside a 6.04% profit margin, which is thin for a provider in a reimbursement-dependent business. That margin is the main reason Efficiency stops short of Excellent: there is limited cushion if pricing comes under pressure. A Good rating on the Solvency Index indicates the balance sheet can handle current obligations, though that cushion matters more now that the policy outlook has grown less predictable.
Where the picture becomes more nuanced is in the market-facing measures. DVA is rated Fair on both the Total Return Index and the Volatility Index, and the stock's path over the past two months explains both. A decline of nearly 30% from the August 3 high has eroded shareholder returns, even though the company beat estimates and reaffirmed guidance during that stretch. Today's 7.22% drop on the HHS announcement shows why the Volatility Index is not rated higher. DaVita's concentrated position in a government-shaped market leaves the stock exposed to sharp moves on policy headlines, regardless of quarterly execution. At a forward P/E of 15.30, the valuation already reflects some of that risk, but not enough to keep the shares from repricing abruptly today.
Within the Health Care sector, DaVita is on par with Medtronic plc (MDT, B-) and HCA Healthcare, Inc. (HCA, B-). It trails McKesson Corporation (MCK, B) and Cencora, Inc. (COR, B), while Cardinal Health, Inc. (CAH, B+) carries the strongest rating of the group. Notably, none of those peers face the same direct exposure to dialysis-market policy that DaVita now confronts.
About DaVita Inc.
DaVita Inc. (DVA) is a Health Care company and one of the largest providers of kidney care services in the United States. Its core business is dialysis for patients with chronic kidney failure and end-stage kidney disease. The company delivers that care primarily through a nationwide network of outpatient dialysis centers, along with inpatient dialysis services provided under contracts with hospitals. DaVita also operates internationally, providing dialysis services in a number of markets outside the United States.
Beyond in-center treatment, DaVita offers home dialysis programs covering both peritoneal dialysis and home hemodialysis. These options are becoming more strategically important as policymakers push care toward the home. The company has also expanded into integrated kidney care, participating in value-based arrangements that tie its compensation to managing the overall health and cost of care for kidney patients, not just individual treatments. This broader model reaches earlier into the disease and aims to reduce hospitalizations and improve outcomes over the full course of a patient's illness.
DaVita's competitive advantages rest on scale, clinical experience, and established relationships with nephrologists, hospitals, and payers. Its large center network gives it purchasing leverage, operating efficiencies, and data on patient outcomes that smaller operators cannot easily match. Those same advantages make the company's market share a focal point for regulators. Its heavy reliance on government programs such as Medicare also means reimbursement policy remains one of the most important variables shaping its business.
Investor Outlook
DaVita Inc. (DVA) holds a Weiss Rating of B- (Buy), backed by solid earnings growth that now sits against a newly uncertain policy backdrop. Investors should watch the October 29 Q3 report for any change to the $14.10 to $15.20 EPS guidance and for management's read on how the Kidney Care National Plan could affect competition, home-care economics, and reimbursement. See full rankings of all B- rated Health Care stocks inside the Weiss Stock Screener.
--